3095 completed, 732 recruiting, 720 terminated, 621 unknown. 5939 Phase 1, 1993 Phase 2.
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Immunotherapy Treating GI Cancer engineered immune cells - Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-11-02 |
| CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 1 | Not yet recruiting | City of Hope Medical Center | 36 | 2027-05-06 | 2026-09-25 |
| Daraxonrasib in Resectable PDAC Daraxonrasib, Surgical Resection, Adjuvant Chemotherapy - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Not yet recruiting | Dana-Farber Cancer Institute | 30 | 2027-04-13 | 2026-10-27 |
| A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer EF-009 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Everfront Biotech Co., Ltd. | 30 | 2027-04-01 | 2026-09-11 |
| LMT503 First-in-human SAD, MAD, and FE Study LMT503, Placebo - Inflammatory Bowel Disease, Colitis, Ulcerative | Phase 1 | Not yet recruiting | Lmito Therapeutics Inc. | 72 | 2027-03-01 | 2026-09-01 |
| Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications Autologous adipose derived mesenchymal stromal cells (AMSC) - Liver Transplant; Complications, Liver Diseases | Phase 1 | Not yet recruiting | Mayo Clinic | 20 | 2027-02-01 | 2026-04-06 |
| Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) Ulonivirine - Hepatic Insufficiency | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 22 | 2027-01-22 | 2026-07-16 |
| A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) AVIHepC1, Normal Saline - Hepatitis C | Phase 1 | Not yet recruiting | University of Alberta | 27 | 2027-01-15 | 2026-09-25 |
| A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer Navlimetostat, mFOLFIRINOX Treatment Regimen - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | Not yet recruiting | Daniel Nussbaum, M.D. | 18 | 2027-01-15 | 2026-11-02 |
| A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). ST316 IV - Familial Adenomatous Polyposis (FAP) | Phase 1 | Not yet recruiting | Sapience Therapeutics | 40 | 2027-01-04 | 2026-08-12 |
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Outside the Cage (OTC) Robotic Esophagectomy OTC MIE Esophagectomy - Esophageal Cancer | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 31 | 2027-01-01 | 2026-03-18 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 15 | 2026-12-16 | 2026-05-27 |
| Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis ATTO-1091, Placebo - Ulcerative Colitis (UC) | Phase 1 | Not yet recruiting | Attovia Therapeutics Inc | 96 | 2026-12-14 | 2026-09-15 |
| A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) DES-1357 - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Not yet recruiting | D. E. Shaw Research, LLC | 88 | 2026-12-03 | 2026-09-08 |
| ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Anova Innovation Limited | 84 | 2026-12-01 | 2026-10-23 |
Showing 20 of 5939. Sign in to see all of them.
Colorectal Neoplasms (1247) · Pancreatic Neoplasms (1056) · Stomach Neoplasms (658) · Carcinoma, Hepatocellular (609) · Carcinoma, Non-Small-Cell Lung (563) · Colonic Neoplasms (432) · Breast Neoplasms (425) · Ovarian Neoplasms (394) · Neoplasms (384) · Esophageal Neoplasms (381) · Neoplasm Metastasis (344) · Rectal Neoplasms (312) · Liver Neoplasms (282) · Melanoma (276) · Lung Neoplasms (275)
Neoplasms by Site (3684) · Digestive System Neoplasms (3665) · Neoplasms (3408) · Gastrointestinal Diseases (3125) · Gastrointestinal Neoplasms (2215) · Intestinal Diseases (2191) · Liver Diseases (1791) · Colonic Diseases (1713) · Intestinal Neoplasms (1599) · Neoplasms by Histologic Type (1544) · Rectal Diseases (1495) · Endocrine System Diseases (1391) · Endocrine Gland Neoplasms (1352) · Pancreatic Diseases (1326)
Gemcitabine (334) · Fluorouracil (237) · Oxaliplatin (235) · pembrolizumab (201) · Capecitabine (200) · Bevacizumab (172) · Irinotecan (170) · Leucovorin (170) · Nivolumab (142) · Cisplatin (139) · Cetuximab (136) · 130-nm albumin-bound paclitaxel (134) · Radiotherapy (114) · Cyclophosphamide (102) · Paclitaxel (101)
National Cancer Institute (NCI) (188) · M.D. Anderson Cancer Center (87) · Pfizer (82) · GlaxoSmithKline (81) · Merck Sharp & Dohme LLC (76) · Bristol-Myers Squibb (74) · AstraZeneca (71) · Eli Lilly and Company (59) · Novartis Pharmaceuticals (57) · Mayo Clinic (52) · Boehringer Ingelheim (49) · Gilead Sciences (47) · Hoffmann-La Roche (43) · Memorial Sloan Kettering Cancer Center (43) · Vertex Pharmaceuticals Incorporated (38)
United States (3066) · China (892) · United Kingdom (400) · South Korea (388) · Spain (349) · Australia (330) · France (312) · Canada (301) · Germany (287) · Japan (249) · Belgium (206) · Taiwan (196) · Netherlands (194) · Italy (189) · New Zealand (109)
PMID 33331662, PMID 37983082, PMID 39863139, PMID 19192962, PMID 22473314, PMID 31215818, PMID 37598000, PMID 40056080, PMID 17560413, PMID 17903050, PMID 18590344, PMID 18590345, PMID 19949018, PMID 21488067, PMID 22002018, PMID 22607579, PMID 22634621, PMID 26808342, PMID 27009167, PMID 27257978, PMID 27490698, PMID 27816492, PMID 28735965, PMID 29703432, PMID 30277655, PMID 30625297, PMID 31401903, PMID 31527168, PMID 32671834, PMID 32939319, PMID 33001135, PMID 33317695, PMID 34017343, PMID 34256305, PMID 35046060, PMID 35219300, PMID 35227647, PMID 35362047, PMID 35537408, PMID 35728046, PMID 35771259, PMID 36897458, PMID 36977960, PMID 37082579, PMID 37290591, PMID 37319354, PMID 37496366, PMID 37590355, PMID 37788341, PMID 37917289
2023 (58), 2016 (49), 2017 (41), 2025 (40), 2015 (37), 2019 (36), 2018 (35), 2014 (25), 2009 (24), P30CA033572 (20), 2008 (14), P30CA016672 (14), UM1CA186689 (13), P30CA015083 (11), UM1CA186644 (10)